Inside the Clinic: Updates in Diagnosis, Treatment, and Management of Chronic Graft-Versus-Host Disease - Episode 6

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

April 8, 2022

Corey S. Cutler, MD, MPH, FRCPC, Yi-Bin Chen, MD, Haris Ali, MD, City of Hope

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Background on Graft-vs-Host Disease: Risk Factors and Prevention

EP. 2: Acute vs Chronic GVHD: Identification and Stratification

EP. 3: Frontline Treatment Options for Chronic GVHD

EP. 4: Defining Steroid-Refractory and Steroid-Dependent GVHD

EP. 5: Identifying and Managing Steroid-Refractory Chronic GVHD

Now Viewing

EP. 6: Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

EP. 7: Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

EP. 8: Mechanism of Action of Ruxolitinib

EP. 9: REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

EP. 10: Chronic GVHD: Real-World Use of Ruxolitinib

EP. 11: Selecting Second-Line Therapy for Chronic GVHD

EP. 12: Chronic GVHD: Novel Treatment Approaches With Approved Agents

EP. 13: Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials

EP. 14: HSCT Approaches to Retain GVL While Preventing GVHD

EP. 15: Emerging Treatment Strategies for Chronic GVHD